Charles Schwab
NRC icon

Charles Schwab’s NRC Health Common Stock NRC Stock Holding History

Charles Schwab’s Portfolio NRC Stock Details NRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.44M Buy
113,312
+938
+0.8% +$17.4K ﹤0.01% 2721
2026
Q1 		$1.91M Sell
112,374
-2,593
-2% -$44.1K ﹤0.01% 2731
2025
Q4 		$2.16M Buy
114,967
+18,067
+19% +$273K ﹤0.01% 2741
2025
Q3 		$1.24M Sell
96,900
-14,144
-13% -$212K ﹤0.01% 2885
2025
Q2 		$1.87M Sell
111,044
-8,477
-7% -$115K ﹤0.01% 2687
2025
Q1 		$1.53M Sell
119,521
-5,190
-4% -$83.3K ﹤0.01% 2699
2024
Q4 		$2.2M Buy
124,711
+970
+0.8% +$18.4K ﹤0.01% 2647
2024
Q3 		$2.83M Buy
123,741
+7,866
+7% +$178K ﹤0.01% 2601
2024
Q2 		$2.66M Buy
115,875
+1,786
+2% +$55.1K ﹤0.01% 2602
2024
Q1 		$4.52M Buy
114,089
+1,470
+1% +$58.1K ﹤0.01% 2326
2023
Q4 		$4.46M Buy
112,619
+1,185
+1% +$49.6K ﹤0.01% 2361
2023
Q3 		$4.94M Buy
111,434
+4,895
+5% +$214K ﹤0.01% 2268
2023
Q2 		$4.64M Buy
106,539
+1,736
+2% +$76.3K ﹤0.01% 2261
2023
Q1 		$4.56M Buy
104,803
+1,135
+1% +$50.1K ﹤0.01% 2248
2022
Q4 		$3.87M Buy
103,668
+1,218
+1% +$47.1K ﹤0.01% 2347
2022
Q3 		$4.08M Buy
102,450
+3,490
+4% +$129K ﹤0.01% 2319
2022
Q2 		$3.79M Buy
98,960
+204
+0.2% +$7.38K ﹤0.01% 2307
2022
Q1 		$3.92M Buy
98,756
+2,419
+3% +$94.7K ﹤0.01% 2388
2021
Q4 		$4M Buy
96,337
+818
+0.9% +$35.6K ﹤0.01% 2457
2021
Q3 		$4.03M Buy
95,519
+1,299
+1% +$65.4K ﹤0.01% 2469
2021
Q2 		$4.33M Buy
94,220
+2,627
+3% +$125K ﹤0.01% 2420
2021
Q1 		$4.29M Buy
91,593
+2,953
+3% +$144K ﹤0.01% 2371
2020
Q4 		$3.79M Sell
88,640
-3,127
-3% -$161K ﹤0.01% 2352
2020
Q3 		$4.52M Buy
91,767
+3,468
+4% +$192K ﹤0.01% 2112
2020
Q2 		$5.14M Buy
88,299
+8,509
+11% +$450K ﹤0.01% 2014
2020
Q1 		$3.63M Buy
79,790
+1,407
+2% +$84.5K ﹤0.01% 1995
2019
Q4 		$5.17M Buy
78,383
+6,505
+9% +$398K ﹤0.01% 1998
2019
Q3 		$4.15M Buy
71,878
+4,299
+6% +$266K ﹤0.01% 2065
2019
Q2 		$3.89M Buy
67,579
+1,396
+2% +$64.6K ﹤0.01% 2091
2019
Q1 		$2.56M Buy
66,183
+4,271
+7% +$167K ﹤0.01% 2278
2018
Q4 		$2.36M Buy
61,912
+2,480
+4% +$95.3K ﹤0.01% 2274
2018
Q3 		$2.29M Buy
59,432
+2,835
+5% +$107K ﹤0.01% 2390
2018
Q2 		$2.12M Buy
56,597
+13,146
+30% +$458K ﹤0.01% 2359
2018
Q1 		$1.27M Buy
43,451
+1,287
+3% +$43.2K ﹤0.01% 2451
2017
Q4 		$1.57M Buy
42,164
+4,952
+13% +$176K ﹤0.01% 2386
2017
Q3 		$1.4M Buy
37,212
+6,759
+22% +$212K ﹤0.01% 2420
2017
Q2 		$820K Buy
30,453
+190
+0.6% +$4.64K ﹤0.01% 2529
2017
Q1 		$597K Buy
30,263
+1,710
+6% +$31.6K ﹤0.01% 2584
2016
Q4 		$543K Buy
28,553
+1,540
+6% +$25.4K ﹤0.01% 2620
2016
Q3 		$441K Buy
27,013
+1,360
+5% +$21.4K ﹤0.01% 2651
2016
Q2 		$352K Buy
25,653
+420
+2% +$5.92K ﹤0.01% 2724
2016
Q1 		$393K Buy
25,233
+510
+2% +$7.48K ﹤0.01% 2677
2015
Q4 		$397K Buy
24,723
+650
+3% +$9.87K ﹤0.01% 2747
2015
Q3 		$288K Buy
24,073
+1,709
+8% +$22.7K ﹤0.01% 2846
2015
Q2 		$318K Buy
22,364
+738
+3% +$10.5K ﹤0.01% 2854
2015
Q1 		$312K Buy
21,626
+1,044
+5% +$14.8K ﹤0.01% 2821
2014
Q4 		$288K Buy
20,582
+549
+3% +$8.07K ﹤0.01% 2857
2014
Q3 		$261K Buy
20,033
+459
+2% +$6.31K ﹤0.01% 2862
2014
Q2 		$274K Sell
19,574
-3,316
-14% -$49.9K ﹤0.01% 2893
2014
Q1 		$380K Buy
22,890
+780
+4% +$13.1K ﹤0.01% 2705
2013
Q4 		$417K Buy
22,110
+5,320
+32% +$93.3K ﹤0.01% 2651
2013
Q3 		$313K Sell
16,790
-1,330
-7% -$22.8K ﹤0.01% 2730
2013
Q2 		$312K Buy
+18,120
New +$289K ﹤0.01% 2713

Other funds holding NRC

Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WIC
Willis Investment Counsel Gainesville, Georgia $2.1B AUM 24.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
FMII
Farmers & Merchants Investments Inc Lincoln, Nebraska $4.13B AUM 32.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Charles Schwab's NRC Position: Q2 2026 in Review

Charles Schwab increased its NRC Health Common Stock (NRC) stake by 0.83% in Q2 2026, buying an estimated $17.4K and bringing the position to 113,312 shares worth $2.44M. The position accounts for ﹤0.01% of the portfolio, ranked #2721.

Charles Schwab first reported a position in NRC in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.17M in Q4 2019. 124 funds tracked by Wall St. Rank hold NRC as of Q2 2026.

  • Charles Schwab held 113,312 shares of NRC Health Common Stock worth $2.44M as of Q2 2026.
  • Charles Schwab bought 938 NRC Health Common Stock shares in Q2 2026, an estimated $17.4K.
  • NRC Health Common Stock made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2721 holding.
  • Charles Schwab first reported a position in NRC Health Common Stock in Q2 2013 and has held it in 53 quarters since.
  • Charles Schwab's NRC Health Common Stock position peaked at $5.17M in Q4 2019.
  • 124 funds tracked by Wall St. Rank held NRC Health Common Stock as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.